Abstract
Background Overgeneralised self-blame and worthlessness are key symptoms of major depressive disorder (MDD) and were previously associated with self-blame-selective changes in connectivity between right superior anterior temporal lobe (rSATL) and subgenual frontal areas. In a previous study, remitted MDD patients successfully modulated guilt-selective rSATL-subgenual cingulate connectivity using real-time functional magnetic resonance imaging (rtfMRI) neurofeedback training, thereby increasing their self-esteem. The feasibility and potential of using this approach in symptomatic MDD were unknown.
Methods This single-blind pre-registered randomised controlled pilot trial tested the clinical potential of a novel self-guided psychological intervention with and without additional rSATL-posterior subgenual cortex (SC) rtfMRI neurofeedback, targeting self-blaming emotions in insufficiently recovered people with MDD and early treatment-resistance (n=43, n=35 completers). Following a diagnostic baseline assessment, patients completed three self-guided sessions to rebalance self-blaming biases and a post-treatment assessment. The fMRI neurofeedback software FRIEND was used to measure rSATL-posterior SC connectivity, while the BDI-II was administered to assess depressive symptom severity as a primary outcome measure.
Results Both interventions were demonstrated to be safe and beneficial, resulting in a mean reduction of MDD symptom severity by 46% and response rates of more than 55%, with no group difference. Secondary analyses, however, revealed a differential response on our primary outcome measure between MDD patients with and without DSM-5 defined anxious distress. Stratifying by anxious distress features was investigated, because this was found to be the most common subtype in our sample. MDD patients without anxious distress showed a higher response to rtfMRI neurofeedback training compared to the psychological intervention, with the opposite pattern found in anxious MDD. We explored potentially confounding clinical differences between subgroups and found that anxious MDD patients were much more likely to experience anger towards others as measured on our psychopathological interview which might play a role in their poorer response to neurofeedback. In keeping with the hypothesis that self-worth plays a key role in MDD, improvement on our primary outcome measure was correlated with increases in self-esteem after the intervention and this correlated with the frequency with which participants employed the strategies to tackle self-blame outside of the treatment sessions.
Conclusions These findings suggest that self-blame-selective rtfMRI neurofeedback training may be superior over a solely psychological intervention in non-anxious MDD, although further confirmatory studies are needed. The self-guided psychological intervention showed a surprisingly high clinical potential in the anxious MDD group which needs further confirmation compared versus treatment-as-usual. Future studies need to investigate whether self-blame-selective rSATL-SC connectivity changes are irrelevant in anxious MDD, which could explain their response being better to the psychological intervention without interfering neurofeedback.
Competing Interest Statement
JM owns IP related to the neurofeedback software used in this article, which is however distributed for free use.
Clinical Trial
ISRCTN10526888
Funding Statement
We are very grateful to all participants of this study and their time and effort. We are also grateful to our funders: the NARSAD independent investigator award to RZ awarded by the Brain & Behavior Research Foundation, the IoPPN at King’s College London as well as the NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Roland Zahn. No personal data will be shared and the data is fully anonymised. The data management plan stipulates access: 5.1. Suitability for sharing The anonymised data are suitable for sharing with collaborators. 5.2. Discovery by potential users of the research data Potential users are pointed to the data through publications and the study website and can apply for data sharing via a collaboration. They will be able to get access to the data directly through data repositories such as the one recently launched at KCL with searchable metadata (www.kcl.ac.uk/library/researchsupport/research-data-management/ DepositPublishPromote/Deposit-your-data-with-Kings.aspx) after an embargo period of 5 years. 5.3. Governance of access Primary decisions will be made by the PI, and subsequently reviewed by an independent advisor. 5.4. The study team’s exclusive use of the data There will be an embargo of 5 years after study completion during which only the original research team and new researchers in the PI’s lab or invited collaborators will have access. 5.5. Restrictions or delays to sharing, with planned actions to limit such restrictions See above 5.6. Regulation of responsibilities of users People outside the research team who want to collaborate and use data will have to agree to a data sharing agreement in line with MRC principles.
